France's Schneider Electric is close to acquiring US software company PTC for about $20 billion, according to the Financial Times. The deal could be announced as soon as Monday, though discussions are still ongoing and not guaranteed. PTC, based in Boston, has a market value of $15.63 billion and recently raised its revenue forecast due to strong demand for its industrial software and AI tools. This acquisition would expand Schneider Electric's software capabilities significantly.
Schneider Electric's near $20 billion deal for US software group PTC provides context for technology sector activity on Pluang. For readers following technology stocks, here is Pluang's market snapshot as of Oct 05, 2026 01:11 WIB: out of 150 priced US technology stocks, 75 rose and 74 fell. Notable movers include AEHR at USD 107.21 (+5.52%), EPAM at USD 108.29 (-5.30%), and NTAP at USD 226.27 (+5.22%), with typical hold times ranging from 15 to 57 days.
Bitcoin's price increased by 0.59% within an hour on October 5, moving from $86,052 to $86,564. During this period, $13.96 million in short positions were liquidated across Binance, Bybit, and OKX, while only $10,000 in long positions were liquidated...
Binance liquidated a single Bitcoin short position worth $2.56 million on its perpetual futures market at a price of $86,567. This liquidation occurred on October 4 at 6:16 p.m. ET and involved closing a short trade, which profits from price declines...
This week in crypto was volatile with Bitcoin briefly surpassing $87k before dropping below $84k. Citi raised its 12-month Bitcoin price target to $113k, signaling bullish sentiment. Among altcoins, Midnight (NIGHT) surged 85%, showing strong accumul...
Oracle has committed $10 million and formed a strategic partnership to support the Nashville Symphony as it restructures. This investment will help the orchestra address its immediate financial challenges, resume its 2026-27 season, and bring back fu...
CSL and Alentis Therapeutics have formed an exclusive global partnership to co-develop and co-promote lixudebart, a novel therapy targeting claudin-1 for kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in m...
